In the last trading session, 2.36 million shares of the Fulcrum Therapeutics Inc (NASDAQ:FULC) were traded, and its beta was 2.10. Most recently the company’s share price was $3.03, and it changed around $0.02 or 0.83% from the last close, which brings the market valuation of the company to $147.93M. FULC currently trades at a discount to its 52-week high of $13.70, offering almost -352.15% off that amount. The share price’s 52-week low was $2.87, which indicates that the current value has risen by an impressive 5.28% since then. We note from Fulcrum Therapeutics Inc’s average daily trading volume that its 10-day average is 0.94 million shares, with the 3-month average coming to 1.63 million.

Fulcrum Therapeutics Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.62. If we narrow it down even further, the data shows that 1 out of 9 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 5 recommended FULC as a Hold, whereas 1 deemed it a Buy, and 1 rated it as Underweight. Fulcrum Therapeutics Inc is expected to report earnings per share of -0.29 for the current quarter.

Fulcrum Therapeutics Inc (NASDAQ:FULC) trade information

Instantly FULC has showed a green trend with a performance of 0.83% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.94 on recent trading dayincreased the stock’s daily price by 23.1%. The company’s shares are currently down -55.11% year-to-date, but still down -16.76% over the last five days. On the other hand, Fulcrum Therapeutics Inc (NASDAQ:FULC) is -13.68% down in the 30-day period. We can see from the shorts that 4.97 million shares have been sold at a short interest cover period of 7.67 day(s).

The consensus price target as assigned by Wall Street analysts is $4, which translates to bulls needing to increase their stock price by 24.25% from its current value. Analyst projections state that FULC is forecast to be at a low of $2 and a high of $23.

Fulcrum Therapeutics Inc (FULC) estimates and forecasts

Fulcrum Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -60.65 percent over the past six months and at a 87.42% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 27.81% in revenue this quarter, and will report an increase of 39.07% in the next quarter. The year-over-year growth rate is expected to be 2,764.67%, up from the previous year.

Analysts predict that the company’s current quarter sales will drop, forecast at -100.00%. Forecasts for the next quarter put sales growth at �.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 1.09%. Fulcrum Therapeutics Inc earnings are expected to increase by 90.17% in 2024, but the outlook is positive 16.40% per year for the next five years.

FULC Dividends

Fulcrum Therapeutics Inc’s next quarterly earnings report is expected to be released in December.

Fulcrum Therapeutics Inc (NASDAQ:FULC)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 1.62% of Fulcrum Therapeutics Inc shares, and 89.70% of them are in the hands of institutional investors. The stock currently has a share float of 91.17%. Fulcrum Therapeutics Inc stock is held by 165.0 institutions, with RA CAPITAL MANAGEMENT, L.P. being the largest institutional investor. By 2024-06-30, it held 18.7302% of the shares, which is about 11.61 million shares worth $71.98 million.

RTW INVESTMENTS, LP, with 9.4314% or 5.85 million shares worth $36.24 million as of 2024-06-30, holds the second largest percentage of outstanding shares.